Money Talks: Why weight-loss drugs will resha...

Though a growing share of the British population is anxious about Islam, they have no reason to be. Islamism, a fringe ideology that believes government and society should be guided by Islamic principles, is the real concern. America cracks down on multinationals’ efforts to shif ...  Show more

After years of stalemate, Yemen’s Iran-backed Houthis are taking territory, including on a Red Sea strait. We ask what has changed, and how the shift fits into the wider regional conflict. As America’s midterm elections approach, we examine the fragmentation of the coalition that ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...

It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ...  Show more